Showing results (211-220 of 241) with videos related to

Sort By:
Pageof 25
Scientific Reports|March 5, 2022
The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanismsEllis Nelissen, Nina Possemis, Nick P Van Goethem, et al.
Nitric Oxide : Biology and Chemistry|December 6, 2021
Capillary hemodynamics and contracting skeletal muscle oxygen pressures in male rats with heart failure: Impact of soluble guanylyl cyclase activatorRamona E Weber, Kiana M Schulze, Trenton D Colburn, et al.
The Journal of Sexual Medicine|April 24, 2010
Sex steroid receptors in male human bladder: expression and biological functionAravinda K Chavalmane, Paolo Comeglio, Annamaria Morelli, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2016
Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthmaArnab Ghosh, Cynthia J Koziol-White, Kewal Asosingh, et al.
Experimental Physiology|June 20, 2025
Effects of soluble guanylyl cyclase stimulation on muscle oxygenation and exercise capacity in heart failure with mildly reduced ejection fractionRamona E Weber, Kiana M Schulze, Andrew G Horn, et al.
British Journal of Pharmacology|June 25, 2026
Pharmacological activation of NO-cGMP signalling attenuates metabolic dysfunction-associated steatohepatitisKrithika Rajeeth, Malte Roessing, Moritz Lehners, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 22, 2021
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney diseaseAgnès Bénardeau, Antje Kahnert, Tibor Schomber, et al.
Kidney International|November 21, 2024
Activating soluble guanylyl cyclase attenuates ischemic kidney damageFalk-Bach Lichtenberger, Minze Xu, Cem Erdoğan, et al.
BJU International|October 21, 2016
Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failurePieter Uvin, Maarten Albersen, Ine Bollen, et al.
Journal of Hypertension|April 8, 2025
The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damageMartina Hüttl, Matúš Miklovič, Olga Gawryś, et al.
Pageof 25